Concepedia

Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study

Sandrine Faivre, Patricia Niccoli, Daniel Castellano, Juan W. Valle, Pascal Hammel, Jean‐Luc Raoul, Aaron I. Vinik, Eric Van Cutsem, Yu Jeong Bang, Seung‐Hoon Lee,

Annals of Oncology · 2016 · 192 citations · 16 references

DOIFull text

Open access

Concepts

References

16

Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors

Éric Raymond, Laëtitia Dahan, Jean‐Luc Raoul et al. · New England Journal of Medicine · 2011 · 2.5K citations

, , +11

In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship.

Dirk B. Mendel, Alexander Laird, Xiaohua Xin et al. · PubMed · 2003 · 2K citations

, , +15

Safety, Pharmacokinetic, and Antitumor Activity of SU11248, a Novel Oral Multitarget Tyrosine Kinase Inhibitor, in Patients With Cancer

Sandrine Faivre, Catherine Delbaldo, Karina Vera et al. · Journal of Clinical Oncology · 2005 · 1.2K citations · Full text

, , +17

Phase 3 trial of everolimus for metastatic renal cell carcinoma

Robert J. Motzer, Bernard Escudier, Stéphane Oudard et al. · Cancer · 2010 · 1.1K citations

, , +17

SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer.

Tinya J. Abrams, Leslie B. Lee, Lesley Murray et al. · PubMed · 2003 · 639 citations

, , +17